| Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. G Sanna, ML Bertolaccini, MJ Cuadrado, H Laing, MA Khamashta, ... The Journal of rheumatology 30 (5), 985-992, 2003 | 622 | 2003 |
| GAPSS: the global anti-phospholipid syndrome score S Sciascia, G Sanna, V Murru, D Roccatello, MA Khamashta, ... Rheumatology 52 (8), 1397-1403, 2013 | 352 | 2013 |
| Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome S Sciascia, G Sanna, V Murru, D Roccatello, MA Khamashta, ... Thrombosis and haemostasis 112 (02), 354-364, 2014 | 275 | 2014 |
| Accuracy of anti–ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta‐analysis FB Karassa, A Afeltra, A Ambrozic, DM Chang, F De Keyser, A Doria, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 257 | 2006 |
| Central nervous system involvement in the antiphospholipid (Hughes) syndrome G Sanna, ML Bertolaccini, MJ Cuadrado, MA Khamashta, GRV Hughes Rheumatology 42 (2), 200-213, 2003 | 237 | 2003 |
| The 2023 ACR/EULAR antiphospholipid syndrome classification criteria M Barbhaiya, S Zuily, R Naden, A Hendry, F Manneville, MC Amigo, ... Arthritis & Rheumatology 75 (10), 1687-1702, 2023 | 229 | 2023 |
| Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature M Ramos-Casals, MJ Cuadrado, P Alba, G Sanna, P Brito-Zerón, ... Medicine 87 (6), 311-318, 2008 | 226 | 2008 |
| Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations G Sanna, M Piga, JW Terryberry, MT Peltz, S Giagheddu, L Satta, ... Lupus 9 (8), 573-583, 2000 | 206 | 2000 |
| Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. DP D'Cruz, S Mellor-Pita, B Joven, G Sanna, J Allanson, J Taylor, ... The Journal of rheumatology 31 (2), 280-285, 2004 | 194 | 2004 |
| The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review S Sciascia, G Sanna, MA Khamashta, MJ Cuadrado, D Erkan, L Andreoli, ... Annals of the rheumatic diseases 74 (11), 2028-2033, 2015 | 183 | 2015 |
| Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’) JL Rodriguez-Garcia, ML Bertolaccini, MJ Cuadrado, G Sanna, ... Annals of the rheumatic diseases 71 (2), 242-244, 2012 | 142 | 2012 |
| Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review S Sciascia, ML Bertolaccini, D Roccatello, MA Khamashta, G Sanna Journal of neurology 261, 1706-1714, 2014 | 136 | 2014 |
| Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities S Sciascia, V Murru, G Sanna, D Roccatello, MA Khamashta, ... Journal of Thrombosis and Haemostasis 10 (12), 2512-2518, 2012 | 134 | 2012 |
| The global anti-phospholipid syndrome score in primary APS S Sciascia, G Sanna, V Murru, D Roccatello, MA Khamashta, ... Rheumatology 54 (1), 134-138, 2015 | 117 | 2015 |
| Cerebral manifestations in the antiphospholipid (Hughes) syndrome G Sanna, D D'Cruz, MJ Cuadrado Rheumatic Disease Clinics 32 (3), 465-490, 2006 | 115 | 2006 |
| Central nervous system lupus: a clinical approach to therapy G Sanna, ML Bertolaccini, A Mathieu Lupus 12 (12), 935-942, 2003 | 113 | 2003 |
| Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach G Sanna, ML Bertolaccini, MA Khamashta Current pharmaceutical design 14 (13), 1261-1269, 2008 | 104 | 2008 |
| Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens MJ Cuadrado, Y Karim, G Sanna, E Smith, MA Khamashta, GRV Hughes The American journal of medicine 118 (3), 246-250, 2005 | 103 | 2005 |
| Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome ML Bertolaccini, G Contento, R Lennen, G Sanna, PJ Blower, MT Ma, ... Journal of autoimmunity 75, 30-38, 2016 | 101 | 2016 |
| Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus GD Sebastiani, M Galeazzi, A Tincani, JC Piette, J Font, F Allegri, ... Scandinavian journal of rheumatology 28 (6), 344-351, 1999 | 98 | 1999 |
